Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1999-8-26
pubmed:abstractText
A new human fusion partner, ICLU-T was established for making human T-T hybridomas. Some 6-thioguanine resistant (6-TGr) clones were separated from human T cell acute lymphocytic leukemia, PEER. The fastest growing clone of the 6-TGr cells was scaled up and was cultured in serum free medium. The clone that proliferated most quickly in the serum free medium was separated and named ICLU-T. When ICLU-T was fused with human peripheral blood lymphocytes by using only polyethylene glycol, the viability of fused cells was below 20% just after fusion and the fusion efficiency was 0.01-0.02 per 10(5) parent cells. Whereas, the combined use of 1% lecithin with polyethylene glycol increased the viability over 50% and the fusion efficiencies over 0.2 per 10(5) parent cells on the average. In a total of 34 clones of obtained hybridomas, there were 25 CD2 positive clones. CD4 positive or CD8 positive clones of the CD2 positive clones were 12 and 5 clones, respectively. Further, 4 clones of all hybridomas were CD19 positive, and one clone of these hybridomas was an Ig producer. These obtained hybridomas could proliferate in serum free medium.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1093-2607
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
83-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Establishment of a human fusion partner for making human T-T hybridomas which can grow in serum free medium.
pubmed:affiliation
National Research Institute of Vegetables, Ornamental Plants and Tea, Shizuoka, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't